REGENXBIO Faces Class Action Over Alleged Fraud in Gene Therapy Trial Disclosures
Schall Law Firm seeks $RGNX investors for securities fraud class action alleging false statements about RGX-111 candidate, following tumor discovery in trial participant.
RGNXsecurities fraudclass action lawsuit